Mazza, Gina L. http://orcid.org/0000-0002-5305-6193
Dueck, Amylou C.
Ginos, Brenda
Jansen, Jennifer
Deal, Allison M.
Carr, Philip
Blinder, Victoria S.
Thanarajasingam, Gita
Jonsson, Mattias
Lee, Minji K.
Rogak, Lauren J.
Mody, Gita N.
Schrag, Deborah
Basch, Ethan
Funding for this research was provided by:
Patient-Centered Outcomes Research Institute (IHS-1511-33392)
National Cancer Institute (U01CA233046, P30CA016086)
University Cancer Research Fund of North Carolina
Article History
Accepted: 29 April 2024
First Online: 21 May 2024
Declarations
:
: Dr. Basch reported receipt of personal fees from Navigating Cancer, Sivan, AstraZeneca, Resilience, and the Research Triangle Institute for serving as a scientific advisor; receipt of research funding from the National Cancer Institute (NCI); being owner of Carolina Informatics; and employment by the University of North Carolina. Dr. Schrag reported receipt of personal fees from Pfizer, nonfinancial support from Grail for serving as a site principal investigator, and grants from the American Association for Cancer Research awarded to Memorial Sloan Kettering Cancer Center. Dr. Mody reported consultancy and receipt of research funding from Sivan. All remaining authors have declared no conflicts of interest.
: Informed consent was obtained from all participants included in the PRO-TECT trial.
: The PRO-TECT trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The trial’s protocol was approved by the central institutional review board and the institutional review board at each participating site.